Gilead Stock Reverses; Why Its Buy-Side Miss Isn't The End For Its New HIV Shot

Published 1 week ago • Oct 31, 2025 at 2:53 PM • Negative

Auto

Gilead stock reversed higher on smaller losses early Friday as analysts noted encouraging indicators for its newly approved HIV prevention shot.

Continue Reading

View Comments

More News

Dow Jones Futures Rise With Shutdown Deal 'Coming Together'; Nvidia Leads Four Stocks In Buy Areas

32 minutes ago Neutral

Why Poet Technologies Stock Soared 16.2% in October

1 hour ago Positive

Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial

1 hour ago Positive

AVITA Medical to Host Investor Webinar Briefing

1 hour ago Negative

Why Nvidia Stock Plummeted This Week